Personalized NFTs as a Trial Participation Incentive
Launched by INSTITUTE FOR DIGITAL MEDICINE (WISDM) · Oct 15, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of NFTs, which are unique digital items stored on a secure online system called blockchain, as a way to encourage people to participate in research studies. The goal is to see if offering these digital collectibles can motivate healthy volunteers to join clinical trials, especially as new technologies become more important in healthcare. In this study, 15 healthy individuals will create personalized digital profiles using a special AI platform, and these profiles will be turned into NFTs that participants can keep, display, or trade.
To be eligible for this trial, participants must be healthy adults who can understand and communicate in English and agree to have their interviews recorded. They should also have no significant cognitive impairments. Participants can expect to be involved in interviews to share their thoughts on the use of NFTs as an incentive. This trial is important because it combines innovative technology and personalized medicine to find new ways to engage people in health research, potentially changing the future of how clinical trials are conducted.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy
- • Agree to audio-recording of the interview
- • Meet the cognitive criteria for adequate mental capacity as determined by the MMSE.
- Exclusion Criteria:
- • Difficulty to understand and read English (the DTx text and audio are in English)
- • Significant hearing impairment
- • Evidence/diagnosis of severe cognitive impairment
- • Inability to complete the study at the judgement of the investigators
About Institute For Digital Medicine (Wisdm)
The Institute for Digital Medicine (WisDM) is a leading research organization dedicated to advancing the field of digital health through innovative clinical trials and studies. With a focus on integrating cutting-edge technology and data analytics, WisDM aims to enhance patient outcomes and streamline healthcare delivery. The institute collaborates with healthcare providers, academic institutions, and technology partners to develop evidence-based solutions that leverage digital tools for improved treatment and prevention strategies. Committed to ethical research practices and regulatory compliance, WisDM strives to contribute valuable insights to the evolving landscape of digital medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dean Ho, PhD
Principal Investigator
The Institute for Digital Medicine (WisDM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported